IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in IO Biotech, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +4 vs. Q1 2025
- Shares held
- 18.2M
- −928.9K (−4.9%) vs. Q1 2025
- Total value
- $25.3M
- +$4.44M (+21.3%) vs. Q1 2025
- New holders
- 5
- 5 more added
- Sold out
- 1
- 8 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 132 | $183 | 0.00% | +2+1.5% | Added |
| Citigroup Inc | 314 | $436 | 0.00% | +314 | New |
| Raymond James Financial Inc | 1,000 | $1.39K | 0.00% | +1,000 | New |
| Two Sigma Securities, LLC | 10,385 | $14.4K | 0.00% | +10,385 | New |
| Cubist Systematic Strategies, LLC | 13,096 | $18.2K | 0.00% | +13,096 | New |
| UBS Group AG | 13,259 | $18.4K | 0.00% | +904+7.3% | Added |
| Acadian Asset Management LLC | 23,366 | $32.0K | 0.00% | −7,492−24.3% | Reduced |
| GWM Advisors LLC | 24,217 | $33.7K | 0.00% | +24,217 | New |
| Jane Street Group, LLC | 25,946 | $36.1K | 0.00% | +2,229+9.4% | Added |
| Citadel Advisors LLC | 28,866 | $40.1K | 0.00% | −16,689−36.6% | Reduced |
| XTX Topco Ltd | 29,189 | $40.6K | 0.00% | −21,297−42.2% | Reduced |
| Geode Capital Management, LLC | 33,307 | $46.3K | 0.00% | 00.0% | Unchanged |
| Marex Group plc | 45,000 | $62.5K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 75,000 | $104.3K | 0.00% | 00.0% | Unchanged |
| Sectoral Asset Management Inc | 117,691 | $163.6K | 0.11% | +22,691+23.9% | Added |
| Renaissance Technologies LLC | 139,300 | $193.6K | 0.00% | +12,900+10.2% | Added |
| Soleus Capital Management, L.P. | 192,670 | $267.8K | 0.02% | 00.0% | Unchanged |
| Dauntless Investment Group, LLC | 324,389 | $450.9K | 2.12% | −357,057−52.4% | Reduced |
| Landscape Capital Management, L.L.C. | 347,408 | $482.9K | 0.04% | −52,826−13.2% | Reduced |
| Morgan Stanley | 653,678 | $908.6K | 0.00% | −135,783−17.2% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.20M | 0.74% | 00.0% | Unchanged |
| Bank of America Corp | 1,615,074 | $2.24M | 0.00% | −36,441−2.2% | Reduced |
| PFM Health Sciences, LP | 1,972,073 | $2.74M | 0.24% | −369,034−15.8% | Reduced |
| Marshall Wace, LLP | 2,105,262 | $2.93M | 0.00% | 00.0% | Unchanged |
| Novo Holdings A/S | 3,354,449 | $4.66M | 0.33% | 00.0% | Unchanged |
| Vivo Capital, LLC | 6,173,439 | $8.58M | 0.88% | 00.0% | Unchanged |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −20,029−100.0% | Sold out |